血管内皮生长因子及其受体与血液系统恶性肿瘤的关系研究进展被引量：1

Study Progress on Relationship between Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor and Hematologic Malignancy

原文传递

导出

摘要血管内皮生长因子(VEGF)是最具特征性的血管新生调节因子,与其特异性受体(VEGFR)结合后可促进内皮细胞增殖和分化,增加微血管通透性,诱导血管新生,触发肿瘤细胞的生长并抑制其凋亡。VEGF表达及其信号通路的失调在血液系统恶性肿瘤的发病机制和临床表现方面发挥至关重要的作用,因此直接或间接作用于VEGF及其受体的治疗手段为抑制恶性肿瘤骨髓血管新生、逆转多药耐药提供了全新的方法,从而进一步提高治疗效果。近年来,RNA干扰技术作为一项全新的VEGF抑制体系倍受关注,其中靶向VEGF/VEGFR的小分子干扰RNA可以抑制VEGF表达,从根本上诱导相应基因的沉默。 Vascular endothelial growth factor（VEGF） is one of the best characterized angiogenic regulators which has many effects in promoting endotheliocyte proliferation and differentiation, increasing the microvascular permeability, inducing the angiogenesis, triggering the growth, survival and migration of tumor cells by combining its specificity receptor （VEGFR）. Dysregulation of VEGF expression and signaling pathways therefore plays a pivotal role in the pathogenesis and clinical features of hematologic malignancies, direct and indirect targeting of VEGF and its receptors therefore may provide a potent novel therapeutic approach to overcome bone marrow angiogenesis and multidrug resistance thereby improve patient outcome. Recent years, a novel VEGF blockade system using RNA interference attracts more and more people＇s attention. The small interfering RNA （siRNA） targeting VEGF/VEGFR can completely inhibits the expression of VEGF and induce the silence of corresponding genes.

作者常晓丹陈铭珍

机构地区广东医学院附属医院儿科

出处《实用儿科临床杂志》 CAS CSCD 北大核心 2009年第15期1194-1196,共3页 Journal of Applied Clinical Pediatrics

基金广东省科学技术计划项目资助(83037)

关键词血管内皮生长因子受体血液系统恶性肿瘤 RNA干扰 vascular endothelial growth factor receptor hematologic malignancy ribonucleic acid interference

分类号 R733 [医药卫生—肿瘤]

引文网络
相关文献

参考文献21

1Li WW, Hutnik M, Gehr G. Antiangiogenesis in haematological malignancies [ J ]. Br J Haernatol,2008,143 (5) :622 - 631.
2周慧聪,许培荣,张艳,李继昌.血管内皮生长因子-C在胃癌细胞株和胃癌组织中的表达及其临床意义[J].新乡医学院学报,2008,25(4):353-356. 被引量：5
3Barbarroja N,Velasco F. Intracellular mechanisms involved in the angiogenic process in hematological malignancies [ J ]. Med Clin ( Barc ), 2008,130 ( 15 ) :585 - 590.
4Lyu C J, Rha SY, Won SC. Clinical role of bone marrow angiogenesis in childhood acute lymphocytic leukemia[ J]. Yonsei Med J,2007,48 (2) : 171 - 175.
5李树军,石太新,唐成和.急性白血病患儿骨髓细胞血管内皮生长因子及其受体表达[J].实用儿科临床杂志,2007,22(15):1154-1155. 被引量：5
6Fragoso R, Pereira T, Wu Y, et al. VEGFR - 1 ( FLT - 1 ) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease [ J ]. Blood ,2006,107 (4) :1608 - 1616.
7Santos SC, Dias S. Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways[ J]. Blood,2004,103 ( 10 ) :3883 - 3889.
8Dias S, Hattori K, Zhu Z ,et al. Autocrine stimulation of VEGFR -2 activates human leukemic cell growth and migration [ J ]. J Clin lnvest, 2000,106(4) :511 -521.
9Wegiel B,Ekberg J,Talasila KM,et al. The role of VEGF and a functional link between VEGF and p27 ( Kip1) in acute myeloid leukemia [ J]. Leukemia ,2009,23 (2) :251 - 261.
10Hou HA, Chou WC, Lin LI, et al. Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia[ J ]. Leuk Res,2008,32 (6) :904 - 912.